In vitro Evaluation of Solute Removal Characteristics in Intermittent Infusion Hemodiafiltration.

Hemodiafiltration Infusion flow rate Intermittent infusion hemodiafiltration Solute removal characteristics Time-averaged solute clearance

Journal

Blood purification
ISSN: 1421-9735
Titre abrégé: Blood Purif
Pays: Switzerland
ID NLM: 8402040

Informations de publication

Date de publication:
2019
Historique:
received: 02 10 2019
accepted: 03 10 2019
pubmed: 22 11 2019
medline: 10 5 2020
entrez: 22 11 2019
Statut: ppublish

Résumé

In a typical hemodialysis (HD) session, excessive water removal sometimes induces peripheral circulatory failure and a rapid drop in blood pressure. Intermittent infusion hemodiafiltration (I-HDF), a new modality of dialysis therapy, has been developed to improve peripheral circulation by repeated intermittent infusion of dialysate during an HD session. In a typical I-HDF session, we infuse a volume of 200 mL of ultrapure dialysate by backfiltration at 150 mL/min every 30 min. The same volume is alternately removed from the patient's blood by filtration at a constant rate after each infusion. However, solute removal characteristics in I-HDF have not been clarified previously. We therefore conducted an in vitro study to investigate the characteristics of solute removal and the factors affecting such removal. We used human plasma to evaluate the effects of filtration (QF)/infusion (QI) flow rates on solute clearance (CL) and to estimate the time-averaged solute CL (TACL) values. The CL values for all solutes decreased with increasing QI. For small molecules such as urea, the CL values predominantly decreased with increasing QI because of decreasing diffusive transport. For medium and large solutes such as β2 microglobulin or larger, CL values predominantly increased with increasing QF because of increasing convective transport. However, the effects of these changes on TACL values were small compared with the CL value in a typical HD session because of the alternate filtration and infusion in I-HDF. Key Messages: Solute removal characteristics in I-HDF do not differ significantly from those in conventional HD treatment.

Sections du résumé

BACKGROUND
In a typical hemodialysis (HD) session, excessive water removal sometimes induces peripheral circulatory failure and a rapid drop in blood pressure. Intermittent infusion hemodiafiltration (I-HDF), a new modality of dialysis therapy, has been developed to improve peripheral circulation by repeated intermittent infusion of dialysate during an HD session. In a typical I-HDF session, we infuse a volume of 200 mL of ultrapure dialysate by backfiltration at 150 mL/min every 30 min. The same volume is alternately removed from the patient's blood by filtration at a constant rate after each infusion. However, solute removal characteristics in I-HDF have not been clarified previously. We therefore conducted an in vitro study to investigate the characteristics of solute removal and the factors affecting such removal.
SUMMARY
We used human plasma to evaluate the effects of filtration (QF)/infusion (QI) flow rates on solute clearance (CL) and to estimate the time-averaged solute CL (TACL) values. The CL values for all solutes decreased with increasing QI. For small molecules such as urea, the CL values predominantly decreased with increasing QI because of decreasing diffusive transport. For medium and large solutes such as β2 microglobulin or larger, CL values predominantly increased with increasing QF because of increasing convective transport. However, the effects of these changes on TACL values were small compared with the CL value in a typical HD session because of the alternate filtration and infusion in I-HDF. Key Messages: Solute removal characteristics in I-HDF do not differ significantly from those in conventional HD treatment.

Identifiants

pubmed: 31751993
pii: 000503875
doi: 10.1159/000503875
doi:

Substances chimiques

Dialysis Solutions 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-16

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Takayuki Abe (T)

Department of Clinical Engineering, Tokyo Women's Medical University, Tokyo, Japan, abe.takayuki@twmu.ac.jp.

Isamu Ishimori (I)

Department of Clinical Engineering, Tokyo Women's Medical University, Tokyo, Japan.

Jun Murakami (J)

Department of Clinical Engineering, Tokyo Women's Medical University, Tokyo, Japan.

Michio Mineshima (M)

Department of Clinical Engineering, Tokyo Women's Medical University, Tokyo, Japan.

Norio Hanafusa (N)

Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.

Kosaku Nitta (K)

Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.

Ken Tsuchiya (K)

Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH